Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ERAS-4001 |
| Synonyms | |
| Therapy Description |
ERAS-4001 is a KRAS inhibitor with activity against wild-type KRAS and KRAS G12 mutations, which potentially inhibits growth of KRAS-driven tumor cells (Cancer Res (2025) 85 (8_Supplement_1): 4367). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ERAS-4001 | ERAS 4001|ERAS4001 | KRAS Inhibitor 30 | ERAS-4001 is a KRAS inhibitor with activity against wild-type KRAS and KRAS G12 mutations, which potentially inhibits growth of KRAS-driven tumor cells (Cancer Res (2025) 85 (8_Supplement_1): 4367). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07021898 | Phase I | ERAS-4001 + Pembrolizumab ERAS-4001 + Panitumumab ERAS-4001 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. (BOREALIS-1) | Recruiting | USA | 0 |